Invention Grant
US09546172B2 Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors
有权
吡唑并[3,4-d]嘧啶和吡唑并[2,3-d]嘧啶化合物作为激酶抑制剂
![Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors](/docs/US/2017-01-17/US09546172B2/abs.jpg.600x600.jpg)
- Patent Title: Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors
- Patent Title (中): 吡唑并[3,4-d]嘧啶和吡唑并[2,3-d]嘧啶化合物作为激酶抑制剂
-
Application No.: US14369998Application Date: 2012-12-28
-
Publication No.: US09546172B2Publication Date: 2017-01-17
- Inventor: Wei Chen , David J. Loury
- Applicant: Pharmacyclics LLC
- Applicant Address: US CA Sunnyvale
- Assignee: PHARMACYCLICS LLC
- Current Assignee: PHARMACYCLICS LLC
- Current Assignee Address: US CA Sunnyvale
- Agency: Foley Hoag LLP
- International Application: PCT/US2012/072043 WO 20121228
- International Announcement: WO2013/102059 WO 20130704
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K31/519 ; A61P35/00
![Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors](/abs-image/US/2017/01/17/US09546172B2/abs.jpg.150x150.jpg)
Abstract:
Disclosed herein are compounds such as those of Formula (I) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Public/Granted literature
- US20150018336A1 PYRAZOLO[3,4-d]PYRIMIDINE AND PYRAZOLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS Public/Granted day:2015-01-15
Information query
